You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
With the coronavirus pandemic in recent years, attention has been paid to public health infectious diseases, which have promoted the rapid development of vaccine industry with a large number of technologies emerging. The national "14th Five-Year Plan" for the development of the pharmaceutical industry has clearly proposed that China should strengthen the research and development of new vaccines and industrialization capacity construction, and the policy end supports the construction of new vaccine technology platform including mRNA vaccines.
So far in 2023, what is the trend of domestic and foreign immunization programs and the development of next-generation vaccines based on the coping experience with the pandemic?
To meet the challenges of China's vaccine export in the future, how should we gear to international standards, build up, and improve the quality standard system of international vaccine production？
With the continuous upgrading and innovation of mRNA and circRNA technology, how can we break through technical barriers, establish industrial chain pillars, and solve the problem of large-scale production of nucleic acid vaccine?
Veterinary vaccines has ushered in the high growth of domestic vaccines. How should we expand the booming technology and application of vaccines from human to veterinary use?
What are the innovative technologies and leading advances in the R&D of novel vaccines such as novel adjuvant recombinant vaccines, viral vector vaccines, mucosal vaccines, and broad-spectrum/multivalent vaccines for coronavirus, cancer, and other indications?
VacCon2023 (the 5th Novel Vaccine R&D and Industrialization Forum) will set sail again, with 4 sessions and 13 topic tracks. More than 60 experts from government regulatory agencies, scientific research experts, and leaders of leading enterprises in the field of new vaccines are invited. This year, VacCon2023 will discuss the leading breakthroughs of newresearch, new technologies and new products of RNA/recombinant protein/virus vector vaccine/mucosal vaccines, nano-vaccines, broad-spectrum/multivalent vaccine in the application of coronavirus, cancer, and more indications under the international regulations from human to veterinary use, in order to promote vaccine industry at full speed across the region.
VacCon has been committed to establishing an international industry-university-research platform for the vaccine industry. The first four conferences were successfully held in Shanghai, Guangzhou, Kunming and Chengdu, cumulatively attracting more than 2,000professionals from industry, university, research and medical resources, and inviting more than 120 well-known experts and scholars at home and abroad, as well as leading enterprise R&D scientists to deliver speeches, promoting the transformation, industrialization and application of vaccines in Asia.